Kythera Labs, Inc.

Key Milestones & History:

• Development and Approval of ATX-101 (kybella®): This was the company's flagship achievement, gaining FDA approval and significant market penetration as a non-surgical alternative to liposuction.
• Acquisition by Allergan: Kythera Biopharmaceuticals was acquired by Allergan (now AbbVie) in 2015. This acquisition marked the end of Kythera as a standalone company. The kybella® product line and its associated intellectual property became part of Allergan's portfolio.
• Focus on Aesthetic Medicine: Kythera's entire business model revolved around the aesthetic market, specifically targeting non-invasive cosmetic procedures.

Products:

• kybella® (ATX-101): The deoxycholic acid injection for improvement of moderate to severe fat beneath the chin. This was Kythera's only marketed product before its acquisition.

Business Model:

Kythera's business model relied on the research, development, and commercialization of innovative products within the aesthetic medicine field. The company targeted dermatologists, plastic surgeons, and other medical professionals who perform cosmetic procedures. Post-acquisition, this model continued under Allergan's umbrella.

Current Status:

Kythera Biopharmaceuticals, Inc. no longer exists as an independent company. The product kybella®, its key asset, is now marketed and distributed by AbbVie, which acquired Allergan. Therefore, information regarding financials, leadership, or specific operations would need to be sourced from AbbVie's reporting.